Guiding Principles in Choosing a Therapeutic Table for DCI Hyperbaric Therapy

Total Page:16

File Type:pdf, Size:1020Kb

Guiding Principles in Choosing a Therapeutic Table for DCI Hyperbaric Therapy MINERVA MEDICA COPYRIGHT® MINERVA ANESTESIOL 2009;75:151-61 REVIEW ARTICLE Guiding principles in choosing a therapeutic table for DCI hyperbaric therapy C. ANTONELLI 1, F. FRANCHI 2, M. E. DELLA MARTA 3, A. CARINCI 4, G. SBRANA 2, P. TANASI 1, L. DE FINA 1, M. BRAUZZI 1 1Unit of Diving and Hyperbaric Medicine, Misericordia Hospital, Grosseto, Italy; 2Postgraduate School of Anesthesiology and Intensive Care, University of Siena, Siena, Italy; 3Unit of Orthopedics and Traumatology, Hospital of Stradella, Pavia General Hospital, Pavia, Italy; 4Unit of Acceptance and Urgency Medicine and Surgery, Hospital of Atessa, Lanciano-Vasto General Hospital, Lanciano, Chieti, Italy ABSTRACT Hyperbaric therapy is the basis of treatment for pervasive development disorders. For this reason, the choice of the right therapeutic table for each case is critical. Above all, the delay in recompression time with respect to the first symp- toms and to the severity of the case must be considered. In our experience, the use of low-pressure oxygen tables resolves almost all cases if recompression takes place within a short time. When recompression is possible almost imme- diately, the mechanical effect of reduction on bubble volume due to pressure is of remarkable importance. In these cas- es, high-pressure tables can be considered. These tables can also be used in severe spinal-cord decompression sickness. The preferred breathing mixture is still disputed. Heliox seems to be favored because it causes fewer problems during the recompression of divers, and above all, because nitrox can cause narcosis and contributes nitrogen. Saturation treatment should be avoided or at least used only in special cases. In cases of arterial gas embolism cerebral injury, it is recommended to start with an initial 6 ATA recompression only if the time between symptom onset and the begin- ning of recompression is less than a few hours. Key words: Hyperbaric oxygenation - Decompression - Tables. n the therapeutic treatment of decompression 100% oxygen can be breathed with a low proba- Iillness (DCI), hyperbaric therapy has a promi- bility of oxygen toxicity. Thus, both treated divers nent role; therefore, the choice of the correct ther- and the staff who attend to them in the chamber apeutic table for each case is very important. can be quickly decompressed. The most widely Several recompression schedules (commonly used of these tables are USN5 and USN6 or a sim- referred to as “treatment tables”) have been empir- ilar equivalent. These tables have algorithms that ically developed, based on statistics or tests in allow breathing oxygen at 2.8 ATA and at 1.9 ATA. healthy individuals (e.g., Van Der Aue Tables of The USN6 table can be extended to provide addi- 1945). The initial experience of recompression tional breathing cycles at both depths. An extreme with oxygen tables equivalent to 18 m deep had so example of this is the Catalina table, in which up much success that it became the basis of modern to eight cycles of oxygen can be administered at recompression therapy.1 At 2.8 ATA pressure, 18 m, and 18 cycles can be administered at 9 m. Vol. 75 - No. 3 MINERVA ANESTESIOLOGICA 151 MINERVA MEDICA COPYRIGHT® ANTONELLI THERAPEUTIC TABLE FOR DCI HYPERBARIC THERAPY Many cases of DCI taking place on the surface used in stabilized neurological conditions or resid- can be compressed with satisfactory results using ual painful symptoms.6, 7 In this treatment, the the equivalent 18 m deep pressure while the patient chamber remains under pressure until clinical sta- breathes 100% oxygen, using one of the princi- bilization is reached, usually 12 h or longer. When pal treatment schemes available. U.S. Navy guide- the saturation treatment begins, decompression lines advise the use of table 5 only for mild DCI, must be performed only when a large improve- and symptoms must resolve within 10 min after ment is achieved. Other saturation depths have reaching 18 m. For all other situations, a differ- been proposed and may be compulsory for indi- ent table must be used, usually USN6. viduals decompressing from either deep bounce Most practitioners prefer to use the USN6 table dives or saturation dives.8 In such situations, the for all instances of DCI. Most DCI cases in divers environmental pressure and the treatment gases originating at the surface, therefore, can be man- pressure must be mixed so that the partial pressure aged using USN5 tables, USN6 tables or USN6 of oxygen does not rise above the limits of 0.5 tables with extensions.2 Oxygen cycles are admin- ATA (usually 0.35-4 ATA) and 2.8 ATA, respec- istered at 18 m until the symptoms are relieved or tively. until the patient is clinically stable, for a maxi- Immediate recompression has the greatest suc- mum time allowed by guidelines of the particu- cess, and delays in treatment tend to worsen the lar table. A single treatment is often sufficient to prognosis.9 The effect of delays on the long-term resolve symptoms completely; however, in the case outcome in individual cases, however, is unpre- of residual clinical signs and symptoms, supple- dictable. Although there is partial agreement in mentary treatments must be administered. An the international scientific community about the analysis report by the Divers Alert Network (DAN) effect of delays, it is still a matter of debate. The suggested that this result was probably achieved points of contention are the pressure and the with no more than seven treatments.3 In divers with breathing gas. Pressure reduces bubble volume by severe neurological DCI, however, a greater num- a simple mechanical effect. According to ber of treatments may be required to reach maxi- Bergmann, the maximum bubble reduction is for mum results on the treatment plateau. Multiple pressure from 4 to 6 ATA. Beyond this depth, there recompressions for isolated musculoskeletal (pain is no further benefit. only) DCI are usually not recommended. Generally, the therapeutic pressures used do not More severe cases can be managed using a deep- allow the disappearance of intravascular gaseous er option, e.g., the Comex table 30 or 50, in which sleeves formed by bubble confluence, but they pressurization is 30 or 50 m depth, respectively, cause fragmentation and re-direct the gaseous and breathed oxygen is mixed with helium or embolus into the circulation, releasing collateral nitrogen. Animal studies 4 and a published case vessels. Recompression acts on the primary dis- review 5 provide little evidence in favor of treat- ease cause, but not on its secondary effects. ment at pressures >2.8 ATA. After bubbles have Furthermore, the recompression determines new induced secondary pathophysiologic changes, inert gas tissue saturation and requires appropri- reduction in bubble size is just one part of a com- ate decompression.10 In the past, the optimal depth plex therapy, which might include hyperoxygena- was considered 3 ATA. On a USN initiative and tion, rehydration and pharmacotherapy. as a consequence of animal testing conducted by If the chamber complex and staff are capable of Leitch et al., however, it was reduced to 18 m.11 supporting saturation therapy, it should only be The 18-m treatment may be considered too used when the severity of the symptoms are such deep or too shallow. The initial studies of Behnke that marked residual impairment or loss of life et al. seemed to indicate that 10 m was adequate may result if decompression from 60 feet is under- for all cases.12 On the other hand, the human tri- taken.6 These should not be used in the presence als conducted by Goodman et al. indicated that a of numbness, tingling, decreased sensation of shallow treatment depth was associated with a high touch, hypesthesia, limb weakness or bladder treatment failure rate.13 Wilson et al. reported 65 problems without limb paralysis. It is not to be DCI cases treated on 100% oxygen at either 18 152 MINERVA ANESTESIOLOGICA March 2009 MINERVA MEDICA COPYRIGHT® THERAPEUTIC TABLE FOR DCI HYPERBARIC THERAPY ANTONELLI m or 14 m for three 30-min O2 breathing peri- ods. Only 16% of the patients treated at 18 m had Bubbles recurrent symptoms, while 40% of the patient treated with the 14 m table had recurrences.14 Depths >18 m appear to be beneficial, provided Hypoxia there are no hardware restrictions. Anecdotal evi- dence and isolated case reports describe the ben- efits of increased pressure, but there are no report- Endothelial stress ed trials large enough to draw firm conclusions.15 Some authors have also had experiences where Nitric oxide superoxide anion there was rapid resolution of symptoms soon after compression to 50 m, which showed little or no resolution after several hours at 18 m. According Peroxynitrite to several authors, many cases of DCI resolve dur- ing compression to 18 m, especially if treated rap- idly. The available evidence suggests that treat- Perivascular oxidative stress ment at depths shallower than 18 m runs the risk of treatment failure and that treatments deeper than 18 m offer no particular benefit in the major- Activation of leucocytes and endothelial adhesion ity of cases.16 For spinal cord DCI treatment, we must consid- er that hyperbaric oxygen is thought to be able to Figure 1.—Mechanism of activation of leucocytes and endothe- improve reperfusion injury (symptom deterioration lial adhesion. during compression), while it also has beneficial effects in cases of tissue ischemia or inflammato- because it is metabolized by tissues and, therefore, ry phenomena. The effect of the therapy, there- does not accumulate like an inert gas does. This fore, results from an optimal relationship between results in a reduction of the total gas pressure in the the positive and negative effects of the hyperbar- tissues surrounding the bubble, enhancing the rate ic oxygen.
Recommended publications
  • What Chamber Operators Should Know About Ear Barotrauma (And How to Prevent It) Robert Sheffield, CHT and Kevin “Kip” Posey, CHT / June 2018
    LEARN.HYPERBARICMEDICINE.COM International ATMO Education What Chamber Operators Should Know About Ear Barotrauma (and How to Prevent It) Robert Sheffield, CHT and Kevin “Kip” Posey, CHT / June 2018 INTRODUCTION Ear barotrauma (i.e. “ear block”, “ear squeeze”) is the most common complication of hyperbaric treatment. It occurs when the pressure in the hyperbaric chamber is greater than the pressure in the middle ear. It is prevented by patient assessment, patient education, and the appropriate actions of the chamber operator. The chamber operator has an important role in preventing ear barotrauma in hyperbaric patients. OBJECTIVES At the conclusion of this article, the reader will be able to: Describe the anatomy of the middle ear Explain the mechanism of ear barotrauma Describe 3 techniques to equalize middle ear pressure ANATOMY OF THE MIDDLE EAR The middle ear is an air space that separates the external ear canal from the inner ear. The eardrum, called the tympanic membrane (TM), vibrates when sound enters the ear canal. The vibration is transmitted to a series of bones in the middle ear. These bones transmit vibration to another membrane (the oval window) that separates the air‐filled middle ear from the fluid‐filled inner ear, where sound is sensed in the cochlea. The nasopharynx is the area behind the nose and above the palate. The Eustachian tubes open into this area. Because of the location of the Eustachian tube openings, the same things that cause nasal congestion (e.g. allergies, upper respiratory infection) can cause swelling around the opening of the Eustachian tubes, making it more difficult to equalize pressure in the middle ear.
    [Show full text]
  • Vocal Cord Dysfunction JAMES DECKERT, MD, Saint Louis University School of Medicine, St
    Vocal Cord Dysfunction JAMES DECKERT, MD, Saint Louis University School of Medicine, St. Louis, Missouri LINDA DECKERT, MA, CCC-SLP, Special School District of St. Louis County, Town & Country, Missouri Vocal cord dysfunction involves inappropriate vocal cord motion that produces partial airway obstruction. Patients may present with respiratory distress that is often mistakenly diagnosed as asthma. Exercise, psychological conditions, airborne irritants, rhinosinusitis, gastroesophageal reflux disease, or use of certain medications may trigger vocal cord dysfunction. The differential diagnosis includes asthma, angioedema, vocal cord tumors, and vocal cord paralysis. Pulmo- nary function testing with a flow-volume loop and flexible laryngoscopy are valuable diagnostic tests for confirming vocal cord dysfunction. Treatment of acute episodes includes reassurance, breathing instruction, and use of a helium and oxygen mixture (heliox). Long-term manage- ment strategies include treatment for symptom triggers and speech therapy. (Am Fam Physician. 2010;81(2):156-159, 160. Copyright © 2010 American Academy of Family Physicians.) ▲ Patient information: ocal cord dysfunction is a syn- been previously diagnosed with asthma.8 A handout on vocal cord drome in which inappropriate Most patients with vocal cord dysfunction dysfunction, written by the authors of this article, is vocal cord motion produces par- have intermittent and relatively mild symp- provided on page 160. tial airway obstruction, leading toms, although some patients may have pro- toV subjective respiratory distress. When a per- longed and severe symptoms. son breathes normally, the vocal cords move Laryngospasm, a subtype of vocal cord away from the midline during inspiration and dysfunction, is a brief involuntary spasm of only slightly toward the midline during expi- the vocal cords that often produces aphonia ration.1 However, in patients with vocal cord and acute respiratory distress.
    [Show full text]
  • Full Text (PDF)
    REVIEW COPD Physiological and clinical relevance of exercise ventilatory efficiency in COPD J. Alberto Neder1, Danilo C. Berton1,2, Flavio F. Arbex3, Maria Clara Alencar4, Alcides Rocha3, Priscila A. Sperandio3, Paolo Palange5 and Denis E. O’Donnell1 Affiliations: 1Respiratory Investigation Unit and Laboratory of Clinical Exercise Physiology, Queen’s University and Kingston General Hospital, Kingston, ON, Canada. 2Division of Respiratory Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 3Pulmonary Function and Clinical Exercise Physiology, Respiratory Division, Federal University of Sao Paulo, Sao Paulo, Brazil. 4Division of Cardiology, Federal University of Minas Gerais, Belo Horizonte, Brazil. 5Dept of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. Correspondence: J. Alberto Neder, 102 Stuart Street, Kingston, Ontario, Canada K7L 2V6. E-mail: [email protected] @ERSpublications Ventilatory efficiency is a key measurement for the interpretation of cardiopulmonary exercise testing in COPD http://ow.ly/1nsY307pbz8 Cite this article as: Neder JA, Berton DC, Arbex FF, et al. Physiological and clinical relevance of exercise ventilatory efficiency in COPD. Eur Respir J 2017; 49: 1602036 [https://doi.org/10.1183/13993003.02036- 2016]. ABSTRACT Exercise ventilation (V′E) relative to carbon dioxide output (V′CO2) is particularly relevant to patients limited by the respiratory system, e.g. those with chronic obstructive pulmonary disease (COPD). ′ − ′ High V E V CO2 (poor ventilatory efficiency) has been found to be a key physiological abnormality in symptomatic patients with largely preserved forced expiratory volume in 1 s (FEV1). Establishing an ′ − ′ association between high V E V CO2 and exertional dyspnoea in mild COPD provides evidence that exercise intolerance is not a mere consequence of detraining.
    [Show full text]
  • Critical Care in the Monoplace Hyperbaric Chamber
    Critical Care in the Monoplace Hyperbaric Critical Care - Monoplace Chamber • 30 minutes, so only key points • Highly suggest critical care medicine is involved • Pitfalls Lindell K. Weaver, MD Intermountain Medical Center Murray, Utah, and • Ventilator and IV issues LDS Hospital Salt Lake City, Utah Key points Critical Care in the Monoplace Chamber • Weaver LK. Operational Use and Patient Care in the Monoplace Chamber. In: • Staff must be certified and experienced Resp Care Clinics of N Am-Hyperbaric Medicine, Part I. Moon R, McIntyre N, eds. Philadelphia, W.B. Saunders Company, March, 1999: 51-92 in CCM • Weaver LK. The treatment of critically ill patients with hyperbaric oxygen therapy. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, and Donovan JW, • Proximity to CCM services (ed). Critical care toxicology: diagnosis and management of the critically poisoned patient. Philadelphia: Elsevier Mosby; 2005:181-187. • Must have study patient in chamber • Weaver, LK. Critical care of patients needing hyperbaric oxygen. In: Thom SR and Neuman T, (ed). The physiology and medicine of hyperbaric oxygen therapy. quickly Philadelphia: Saunders/Elsevier, 2008:117-129. • Weaver LK. Management of critically ill patients in the monoplace hyperbaric chamber. In: Whelan HT, Kindwall E., Hyperbaric Medicine Practice, 4th ed.. • CCM equipment North Palm Beach, Florida: Best, Inc. 2017; 65-95. • Without certain modifications, treating • Gossett WA, Rockswold GL, Rockswold SB, Adkinson CD, Bergman TA, Quickel RR. The safe treatment, monitoring and management
    [Show full text]
  • The Use of Heliox in Treating Decompression Illness
    The Diving Medical Advisory Committee DMAC, Eighth Floor, 52 Grosvenor Gardens, London SW1W 0AU, UK www.dmac-diving.org Tel: +44 (0) 20 7824 5520 [email protected] The Use of Heliox in Treating Decompression Illness DMAC 23 Rev. 1 – June 2014 Supersedes DMAC 23, which is now withdrawn There are many ways of treating decompression illness (DCI) at increased pressure. In the past 20 years, much has been published on the use of oxygen and helium/oxygen mixtures at different depths. There is, however, a paucity of carefully designed scientific studies. Most information is available from mathematical models, animal experiments and case reports. During a therapeutic compression, the use of a different inert gas from that breathed during the dive may facilitate bubble resolution. Gas diffusivity and solubility in blood and tissue is expected to play a complex role in bubble growth and shrinkage. Mathematical models, supported by some animal studies, suggest that breathing a heliox gas mixture during recompression could be beneficial for nitrogen elimination after air dives. In humans, diving to 50 msw, with air or nitrox, almost all cases of DCI can be adequately treated at 2.8 bar (18 msw), where 100% oxygen is both safe and effective. Serious neurological and vestibular DCI with only partial improvements during initial compression at 18 msw on oxygen may benefit from further recompression to 30 msw with heliox 50:50 (Comex therapeutic table 30 – CX30). There have been cases successfully treated on 50:50 heliox (CX30), on the US Navy recompression tables with 80:20 and 60:40 heliox (USN treatment table 6A) instead of air and in heliox saturation.
    [Show full text]
  • Development of the Crew Dragon ECLSS
    ICES-2020-333 Development of the Crew Dragon ECLSS Jason Silverman1, Andrew Irby2, and Theodore Agerton3 Space Exploration Technologies, Hawthorne, California, 90250 SpaceX designed the Crew Dragon spacecraft to be the safest ever flown and to restore the ability of the United States to launch astronauts. One of the key systems required for human flight is the Environmental Control and Life Support System (ECLSS), which was designed to work in concert with the spacesuit and spacecraft. The tight coupling of many subsystems combined with an emphasis on simplicity and fault tolerance created unique challenges and opportunities for the design team. During the development of the crew ECLSS, the Dragon 1 cargo spacecraft flew with a simple ECLSS for animals, providing an opportunity for technology development and the early characterization of system-level behavior. As the ECLSS design matured a series of tests were conducted, including with humans in a prototype capsule in November 2016, the Demo-1 test flight to the ISS in March 2019, and human-in-the-loop ground testing in the Demo-2 capsule in January 2020 before the same vehicle performs a crewed test flight. This paper describes the design and operations of the ECLSS, the development process, and the lessons learned. Nomenclature AC = air conditioning AQM = air quality monitor AVV = active vent valve CCiCap = Commercial Crew Integrated Capability CCtCap = Commercial Crew Transportation Capability CFD = computational fluid dynamics conops = concept of operations COPV = composite overwrapped
    [Show full text]
  • Consensus Conference, the ECHM
    24 Diving and Hyperbaric Medicine Volume 47 No. 1 March 2017 Consensus Conference Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment Daniel Mathieu, Alessandro Marroni and Jacek Kot Abstract (Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving and Hyperbaric Medicine. 2017 March;47(1):24-32.) The tenth European Consensus Conference on Hyperbaric Medicine took place in April 2016, attended by a large delegation of experts from Europe and elsewhere. The focus of the meeting was the revision of the European Committee on Hyperbaric Medicine (ECHM) list of accepted indications for hyperbaric oxygen treatment (HBOT), based on a thorough review of the best available research and evidence-based medicine (EBM). For this scope, the modified GRADE system for evidence analysis, together with the DELPHI system for consensus evaluation, were adopted. The indications for HBOT, including those promulgated by the ECHM previously, were analysed by selected experts, based on an extensive review of the literature and of the available EBM studies. The indications were divided as follows: Type 1, where HBOT is strongly indicated as a primary treatment method, as it is supported by sufficiently strong evidence; Type 2, where HBOT is suggested as it is supported by acceptable levels of evidence; Type 3, where HBOT can be considered as a possible/optional measure, but it is not yet supported by sufficiently strong evidence. For each type, three levels of evidence were considered: A, when the number of randomised controlled trials (RCTs) is considered sufficient; B, when there are some RCTs in favour of the indication and there is ample expert consensus; C, when the conditions do not allow for proper RCTs but there is ample and international expert consensus.
    [Show full text]
  • Code of Federal Regulations GPO Access
    4±23±97 Wednesday Vol. 62 No. 78 April 23, 1997 Pages 19667±19896 Briefings on how to use the Federal Register For information on briefings in Washington, DC, see announcement on the inside cover of this issue. Now Available Online Code of Federal Regulations via GPO Access (Selected Volumes) Free, easy, online access to selected Code of Federal Regulations (CFR) volumes is now available via GPO Access, a service of the United States Government Printing Office (GPO). CFR titles will be added to GPO Access incrementally throughout calendar years 1996 and 1997 until a complete set is available. GPO is taking steps so that the online and printed versions of the CFR will be released concurrently. The CFR and Federal Register on GPO Access, are the official online editions authorized by the Administrative Committee of the Federal Register. New titles and/or volumes will be added to this online service as they become available. http://www.access.gpo.gov/nara/cfr For additional information on GPO Access products, services and access methods, see page II or contact the GPO Access User Support Team via: ★ Phone: toll-free: 1-888-293-6498 ★ Email: [email protected] federal register 1 II Federal Register / Vol. 62, No. 78 / Wednesday, April 23, 1997 SUBSCRIPTIONS AND COPIES PUBLIC Subscriptions: Paper or fiche 202±512±1800 Assistance with public subscriptions 512±1806 General online information 202±512±1530; 1±888±293±6498 FEDERAL REGISTER Published daily, Monday through Friday, Single copies/back copies: (not published on Saturdays, Sundays, or on official holidays), by the Office of the Federal Register, National Archives and Paper or fiche 512±1800 Records Administration, Washington, DC 20408, under the Federal Assistance with public single copies 512±1803 Register Act (49 Stat.
    [Show full text]
  • Symptomatic Middle Ear and Cranial Sinus Barotraumas As a Complication of Hyperbaric Oxygen Treatment
    İst Tıp Fak Derg 2016; 79: 4 KLİNİK ARAŞTIRMA / CLINICAL RESEARCH J Ist Faculty Med 2016; 79: 4 http://dergipark.ulakbim.gov.tr/iuitfd http://www.journals.istanbul.edu.tr/iuitfd SYMPTOMATIC MIDDLE EAR AND CRANIAL SINUS BAROTRAUMAS AS A COMPLICATION OF HYPERBARIC OXYGEN TREATMENT HİPERBARİK OKSİJEN TEDAVİSİ KOMPLİKASYONU: SEMPTOMATİK ORTA KULAK VE KRANYAL SİNUS BAROTRAVMASI Bengüsu MİRASOĞLU*, Aslıcan ÇAKKALKURT*, Maide ÇİMŞİT* ABSTRACT Objective: Hyperbaric oxygen therapy (HBOT) is applied for various diseases. It is generally considered safe but has some benign complications and adverse effects. The most common complication is middle ear barotrauma. The aim of this study was to collect data about middle ear and cranial sinus barotraumas in our department and to evaluate factors affecting the occurrence of barotrauma. Material and methods: Files of patients who had undergone hyperbaric oxygen therapy between June 1st, 2004, and April 30th, 2012, and HBOT log books for the same period were searched for barotraumas. Patients who were intubated and unconscious were excluded. Data about demographics and medical history of conscious patients with barotrauma (BT) were collected and evaluated retrospectively. Results: It was found that over eight years and 23,645 sessions, 39 of a total 896 patients had BT; thus, the general BT incidence of our department was 4.4%. The barotrauma incidence was significantly less in the multiplace chamber (3.1% vs. 8.7%) where a health professional attended the therapies. Most barotraumas were seen during early sessions and were generally mild. A significant accumulation according to treatment indications was not determined. Conclusion: It was thought that the low barotrauma incidence was related to the slow compression rate as well as training patients thoroughly and monitoring them carefully.
    [Show full text]
  • Leonardo User Manual
    Direction for use Computer Leonardo ENGLISH cressi.com 2 TABLE OF CONTENTS Main specifications page 4 TIME SET mode: General recommendations Date and time adjustment page 31 and safety measures page 5 SYSTEM mode: Introduction page 10 Setting of measurement unit and reset page 31 1 - COMPUTER CONTROL 3 - WHILE DIVING: COMPUTER Operation of the Leonardo computer page 13 FUNCTIONS 2 - BEFORE DIVING Diving within no decompression limits page 36 DIVE SET mode: DIVE AIR function: Setting of dive parameters page 16 Dive with Air page 37 Oxygen partial pressure (PO2) page 16 DIVE NITROX function: Nitrox - Percentage of the oxygen (FO2) page 18 Dive with Nitrox page 37 Dive Safety Factor (SF) page 22 Before a Nitrox dive page 37 Deep Stop page 22 Diving with Nitrox page 40 Altitude page 23 CNS toxicity display page 40 PLAN mode: PO2 alarm page 43 Dive planning page 27 Ascent rate page 45 GAGE mode: Safety Stop page 45 Depth gauge and timer page 27 Decompression forewarning page 46 Deep Stop page 46 3 Diving outside no decompression limits page 50 5 - CARE AND MAINTENANCE Omitted Decompression stage alarm page 51 Battery replacement page 71 GAGE MODE depth gauge and timer) page 52 6 - TECHNICAL SPECIFICATIONS Use of the computer with 7 - WARRANTY poor visibility page 56 4 - ON SURFACE AFTER DIVING Data display and management page 59 Surface interval page 59 PLAN function - Dive plan page 60 LOG BOOK function - Dive log page 61 HISTORY function - Dive history page 65 DIVE PROFILE function - Dive profile page 65 PCLINK function Pc compatible interface page 66 System Reset Reset of the instrument page 70 4 Congratulations on your purchase of your Leo - trox) dive.
    [Show full text]
  • Special Operations Rebreathers
    Special Operations Underwater Life Support Systems INTRODUCTION TO JFD JFD is the world leading underwater capability provider facilitating the commercial and defence diving industries by offering innovative diving, submarine rescue and subsea technical solutions. JFD has a well-established history in the development of advanced and innovative diving and submarine rescue systems spanning over 30 years. Our systems continue to set the president in terms of capability and performance and JFD is relied upon by divers worldwide across both the defence and commercial sectors. Our products and services have been delivered to a large number of countries across all continents. With in-service support established in many of these locations and tailored Integrated Logistics Support (ILS) packages, JFD is able to provide high customer equipment availability, rapid technical support and tailored training packages. 2 | Introduction JFD offers two highly capable underwater life support systems to meet the full mission profile of today’s Special Operations diver. A modular approach enables customisation of the life support system in response to demands across the full operational spectrum. SHADOW ENFORCER The solution for extended duration and deeper diving The lightweight solution for short duration mission mission profiles. profiles. 3 | Offering A common life support platform facilitates a multi-mission capability offering numerous operational and logistic benefits that include: ENHANCED MISSION EFFECTIVENESS • Front and back mount options • Oxygen
    [Show full text]
  • Hyperbaric Oxygen Therapy (HBOT) Final Evidence Report
    20, 2012 Health Technology Assessment Hyperbaric Oxygen Therapy (HBOT) for Tissue Damage, Including Wound Care and Treatment of Central Nervous System (CNS) Conditions Final Evidence Report February 15, 2013 Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia, WA 98504-2712 (360) 725-5126 hta.hca.wa.gov [email protected] Hyperbaric Oxygen Therapy (HBOT) for Tissue Damage, Including Wound Care and Treatment of Central Nervous System (CNS) Conditions A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – February 15, 2013 Acknowledgement This report was prepared by: Hayes, Inc. 157 S. Broad Street Suite 200 Lansdale, PA 19446 P: 215.855.0615 F: 215.855.5218 This report is intended to provide research assistance and general information only. It is not intended to be used as the sole basis for determining coverage policy or defining treatment protocols or medical modalities, nor should it be construed as providing medical advice regarding treatment of an individual’s specific case. Any decision regarding claims eligibility or benefits, or acquisition or use of a health technology is solely within the discretion of your organization. Hayes, Inc. assumes no responsibility or liability for such decisions. Hayes employees and contractors do not have material, professional, familial, or financial affiliations that create actual or potential conflicts of interest related to the preparation of this report. Prepared by Winifred Hayes, Inc. Page i February
    [Show full text]